Forsta AP Fonden Sells 1,000 Shares of Humana Inc. (NYSE:HUM)

Forsta AP Fonden decreased its position in shares of Humana Inc. (NYSE:HUM) by 4.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,200 shares of the insurance provider’s stock after selling 1,000 shares during the quarter. Forsta AP Fonden’s holdings in Humana were worth $6,403,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in HUM. Vanguard Group Inc. grew its position in shares of Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. Dodge & Cox lifted its position in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares during the period. Pzena Investment Management LLC lifted its holdings in shares of Humana by 6.1% in the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock valued at $1,013,133,000 after buying an additional 219,541 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Humana by 11.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,605,771 shares of the insurance provider’s stock worth $407,401,000 after buying an additional 160,952 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Humana by 14.5% in the 4th quarter. Northern Trust Corp now owns 1,216,195 shares of the insurance provider’s stock worth $308,561,000 after purchasing an additional 153,739 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 4.1%

Shares of Humana stock opened at $266.65 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock’s 50 day simple moving average is $237.88 and its 200-day simple moving average is $253.89. The stock has a market cap of $32.07 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.57 and a beta of 0.44. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analysts’ expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.96 EPS. Analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Barclays set a $275.00 target price on shares of Humana and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Piper Sandler decreased their price objective on shares of Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research report on Thursday, July 31st. Morgan Stanley dropped their target price on Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 31st. Wells Fargo & Company set a $348.00 price target on Humana in a research note on Friday, July 18th. Finally, Truist Financial lowered their price target on Humana from $280.00 to $260.00 and set a “hold” rating on the stock in a research report on Wednesday, July 16th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $281.62.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.